LD, M., P, T., & AC, L. (2019). CPX-351: A nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties. Dove Medical Press.
Chicago Style (17th ed.) CitationLD, Mayer, Tardi P, and Louie AC. CPX-351: A Nanoscale Liposomal Co-formulation of Daunorubicin and Cytarabine with Unique Biodistribution and Tumor Cell Uptake Properties. Dove Medical Press, 2019.
MLA (8th ed.) CitationLD, Mayer, et al. CPX-351: A Nanoscale Liposomal Co-formulation of Daunorubicin and Cytarabine with Unique Biodistribution and Tumor Cell Uptake Properties. Dove Medical Press, 2019.
Warning: These citations may not always be 100% accurate.